

**HYALOSE CHIEF SCIENTIST HONORED AT
7TH INTERNATIONAL CONFERENCE ON HYALURONAN**

Oklahoma City, OK and Austin, TX—May 1, 2007— Emergent Technologies Inc. (ETI) of Austin announced today that Dr. Paul DeAngelis, a Hyalose, L.L.C. Chief Scientist, received the Rooster Award 2007 from the International Society of Hyaluronan Sciences (ISHAS) at its conference held in Charleston, South Carolina, April 22-27, 2007. www.ishas.org The award is engraved "... to acknowledge his work on the development of synthetic hyaluronan..." Dr. DeAngelis is a professor at the University of Oklahoma Health Sciences Center in Oklahoma City.

Mr. Tommy Harlan, CEO of Hyalose and Chairman, CEO, and President of ETI commented, "We are delighted that ISHAS has recognized the accomplishments and contributions that Dr. DeAngelis has made in the field of synthetic hyaluronan. The rooster symbolizes the fact that hyaluronan which is used as a medical device for osteoarthritis treatment and ophthalmic surgeries, was originally extracted and purified from the red comb of a rooster in the 1950's. Previous award recipients were Dr. Endre Balazs, the developer of HA for medical devices and co-founder of Biomatrix, Inc, and Dr. Torvard Laurent, past President of the Royal Swedish Academy of Science and Chairman of the Council for Nobel Prize Foundation." John Hoopingarner, COO of Hyalose and Executive VP of ETI, added, "The work of Dr. DeAngelis has further broadened the development and use of synthetic hyaluronan. Hyalose is now marketing three product lines, SelectHA, PrimeHA, and nanoHA, giving researchers a broad selection of molecular weights from which to choose. Dr. DeAngelis has won three OCAST OARS (State of Oklahoma) grants in addition to NSF and NIH grants which have sustained his academic research efforts and development activities in Hyalose. He has also been instrumental in grooming his promising doctoral students for positions within the ETI companies after graduation."

ETI formed Hyalose in its first investment fund, Emergent-OU, Ltd., in 2000, and manages it from its Austin headquarters. Hyalose licensed the rights to technology patented by Dr. DeAngelis and colleague and fellow Chief Scientist, Dr. Paul Weigel, related to the production of hyaluronan, also known as hyaluronic acid (HA), which is a biopolymer used in formulations for high-end Wound Healing, Drug Delivery, Osteoarthritis, Ophthalmology, Cosmetics and Dermatology, Urology, Tissue Engineering, and Anti-Adhesion Surgical Devices applications. Visit its website at www.hyalose.com

Harlan founded ETI in 1989 and launched its first venture capital fund in 1998. ETI specializes in forming, funding, commercializing, and managing biotech companies for the purpose of converting institutional and university-based technology into high-return ventures. Visit its website at www.etibio.com

Contact: Mr. John Hoopingarner
2508 Ashley Worth Blvd., Suite 200
Austin, TX 78738
(T) 512/697-8205 (F) 512/263-3236